icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Na´ve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders
 
 
  Reported by Jules Levin
47th Annual Meeting of the European Association for the Study of the Liver · Barcelona, Spain · April 18-22, 2012
 
Fred Poordad1, Eric Lawitz2, Kris V. Kowdley3, Gregory T. Everson4, Bradley Freilich5, Daniel Cohen6, Sara Siggelkow6, Michele Heckaman6, Rajeev Menon6, Tami Pilot-Matias6, Thomas Podsadecki6, Barry Bernstein6 1: Cedars-Sinai Medical Center, Los Angeles, CA, 2: Alamo Medical Research, San Antonio, TX, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: University of Colorado Denver and University of Colorado Hospital, Aurora, CO, 5: Kansas City Gastroenterology & Hepatology, Kansas City, MO, 6: Abbott, Abbott Park, IL

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif

EASL13.gif

EASL14.gif

EASL15.gif